Biologic therapy of melanoma with cytokines and lymphocytes

Seminars in Surgical Oncology

Volumn 12, Issue 6, 1996, Pages 436-445

  Bear, Harry D ^a,b   Hamad, Giselle G ^a   Kostuchenko, Paul J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Hematology/Oncology   (United States)

Author keywords

combined antineoplastic agents; combined modality therapy; immunologic adjuvants; immunotherapy; interferons; interleukins; melanoma

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL; HUMAN; IMMUNOSTIMULATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; MELANOMA; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029827591     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<436::AID-SSU9>3.0.CO;2-B     Document Type: Review

References (63)

1. Oettgen HF, Old LJ: The history of cancer immunotherapy. In DeVita VT, Hellman S, Rosenberg SA (eds): "Biologic Therapy of Cancer." Philadelphia: Lippincott, 1991, 87-119.
2. Dvorak HF, Gresser I: Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 81:497-502, 1989.
3. Kirkwood JM, Agarwala S: Systemic cytotoxic and biologic therapy melanoma. PPO Updates 7:1-16, 1993.
4. Creagan ET, Ahmann DL, Frytak S, et al: Three consecutive phase II studies of recombinant Interferon alfa-2a in advanced malignant melanoma. Cancer 59(3 Suppl):638-646, 1987.
5. Mitchell MS, Jakowatz J, Harel W, et al: Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 12:402-411, 1994.
6. Cascinelli N, Bufalino R, Morabito A, Mackie R: Results of adjuvant interferon study in WHO melanoma programme. Lancet 343: 913-914, 1994.
7. Kirkwood JM, Sosman J, Ernstoff MS, et al: E2690: A study of the mechanism of IFN alfa-2b in high-risk melanoma in the ECOG/Intergroup trial E1690. [Abstract 3815.] In "Proceedings of the American Association for Cancer Research, March 18-22, 1995, Toronto, Canada." Linthicum: Cadmus Journal Services, 1995, 641.
8. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783, 1995.
9. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996.
10. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994.
11. Dubinett SM, Huang M, Lichtenstein A, et al: Tumor necrosis factor-α plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation. Cell Immunol 157: 170-180, 1994.
12. Legha SS, Gianan MA, Plager C, et al: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 77:89-96, 1996.
13. Marincola FM: Interleukin-2. Biol Ther Cancer Updates 4:1-16, 1994.
14. Carswell EA, Old LJ, Kassel RL, et al: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
15. Alexander HR, Fraker DL, Bartlert DL: Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 12:416-428, 1996.
16. Keilholz U, Scheibenbogen C, Tilgen W, et al: Interferon-α and interleukin-2 in the treatment of metastatic melanoma: Comparison of two phase II trials. Cancer 72:607-614, 1993.
17. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989.
18. Marincola FM, White DE, Wise AP, Rosenberg SA: Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 13:1110-1122, 1995.
19. Sparano JA, Fisher RI, Sunderland M, et al: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-1977, 1993.
20. Mitchell MS: Chemotherapy in combination with biomodulation: A 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol 19 (2 Suppl 4):80-87, 1992.
21. Dillman RO, Oldham RK, Barth NM, et al: Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: A National Biotherapv Study Group trial. J Natl Cancer Inst 82:1345-1349, 1990.
22. Demchak PA, Mier JW, Robert NJ, et al: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol 9:1821-1830, 1991.
23. Flaherry LE, Robinson W, Redman BG, et al: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 71: 3520-3525, 1993.
24. Atkins MB, O'Boyle KR, Sosman JA, et al: Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12:1553-1560, 1994.
25. Anderson C, Buzaid AC, Legha SS: Systemic treatments for advanced cutaneous melanoma. Oncology 9:1149-1158, 1995.
26. Legha SS, Ring S, Bedikian A, et al: Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D), and alpha interferon (IFN) in patients (PT) with metastatic melanoma (MM). In Perry MC (ed): "Proceedings of the American Society of Clinical Oncology, May 16-18, 1993, Orlando, FL. "Orlando: American Society of Clinical Oncology, 1993, 388.
27. Pyrhönen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10:1919-1926, 1992.
28. Hahka-Kemppinen M, Muhonen T, Virolainen M, et al: Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol 132:973-977, 1995.
29. Falkson CI, Falkson G, Falkson HC: Improved results with the ad dition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991.
30. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992.
31. Legha SS, Buzaid AC: Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 20:27-32, 1993.
32. Heywood GR, Rosenberg SA, Weber JS: Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst 87: 915-922, 1995.
33. Bakker AB, Schreurs MW, De Boer AJ, et al: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994.
34. Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA: Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54:3124-3126, 1994.
35. Rosenberg SA: The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J 1:90-100, 1995.
36. Atzpodien J, Lopez Hanninen E, Kirchner H, et al: Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine. cisplatin, carmustine and tamoxifen. Eur J Cancer 31A:876-881, 1995
37. Rosenberg SA, Lotze MT, Muul LM, et al: Special report. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985.
38. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.
39. Bar MH, Sznol M, Atkins MB, et al: Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 8: 1138-1147, 1990.
40. West WH, Tauer KW, Yannelli JR, et al: Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987.
41. Dutcher JP, Gaynor ER, Boldt DH, et al: A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9: 641-648, 1991.
42. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-632, 1993.
43. Koretz MJ, Lawson DH, York RM, et al: Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 126:898-903, 1991.
44. Turtte TM, Inge TH, Lind DS, Bear HD: Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumor metastases. Surg Oncol 1:299-307, 1992.
45. Rosenberg SA, Packard BS, Aebersold PM, et al: Special report: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1680, 1988
46. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994.
47. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995.
48. Hwu P, Yannelli J, Kriegler M, et al: Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α cDNA for the gene therapy of cancer in humans. J Immunol 150:4104-4115, 1993.
49. Dillman RO, Oldham RK, Barth NM, et al: Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma: A National Biotherapy Study Group trial. Cancer 68:1-8, 1991.
50. Goedegebuure PS, Douville LM, Li H, et al: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study J Clin Oncol 13:1939-1949, 1995.
51. Tuttle TM, Inge TH, Wirt CP, et al: Bryostatin 1 activates T cells that have antitumor activity. J Immunother 12:75-81, 1992.
52. Darrow TL, Slingluff CL, Seigler HF: Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer 62:84-91, 1988.
53. Yoshizawa H, Sakai K, Chang AE, Shu S: Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 134:473-479, 1991.
54. Chang AE, Yoshizawa H, Sakai K, et al: Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043-1050, 1993.
55. Nabel GJ, Yang ZY, Nabel EG, et al: Direct gene transfer for treatment of human cancer. Ann N Y Acad Sci 772:227-231, 1995.
56. Tuttle TM, Inge TH, Bethke KP, et al: Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res 52:548-553, 1992.
57. Slingluff CL Jr Tumor antigens and tumor vaccines: Peptides as immunogens. Semin Surg Oncol 12:446-153, 1996.
58. Irvine KR, Rao JB, Rosenberg SA, Restifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238-245, 1996.
59. Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993.
60. Ron IG, Mordish Y, Eisenthal A, et al: A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-α2a in patients with advanced malignant melanoma. Cancer Immunol Immunother 38:379-384, 1994.
61. Rixe O, Benhammouda A, Antoine E, et al: Final results of a prospective multicentric study on 91 metastatic malignant melanoma patients treated by chemoimmunotherapy with cisplatin, interleukin 2 and interferon-α. In Perry MC (ed): "Proceedings of the American Society of Clinical Oncology. May 14-17, 1994, Dallas, TX." Dallas: American Society of Clinical Oncology, 1994, 399.
62. Sznol M, Clark JW, Smith JW 2nd, et al: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 84:929-937, 1992.
63. Legha SS, Buzaid AC, Ring S, et al: Improved results of treatment of metastatic melanoma with combined use of biotherapy and chemotherapy. In Perry MC (ed): "Proceedings of the American Society of Clinical Oncology, May 14-17, 1994, Dallas, TX." Dallas: American Society of Clinical Oncology, 1994, 394.